Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial.

Détails

ID Serval
serval:BIB_8B4B5AC3FE33
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial.
Périodique
Blood
Auteur(s)
Moreau P., Attal M., Pégourié B., Planche L., Hulin C., Facon T., Stoppa A.M., Fuzibet J.G., Grosbois B., Doyen C., Ketterer N., Sebban C., Kolb B., Chaleteix C., Dib M., Voillat L., Fontan J., Garderet L., Jaubert J., Mathiot C., Esseltine D., Avet-Loiseau H., Harousseau J.L.
Collaborateur(s)
IFM 2005-01 study investigators
ISSN
1528-0020 (Electronic)
ISSN-L
0006-4971
Statut éditorial
Publié
Date de publication
2011
Volume
117
Numéro
11
Pages
3041-3044
Langue
anglais
Notes
Publication types: JOURNAL ARTICLE
Résumé
In the 2005-01 trial, we have demonstrated that bortezomib-dexamethasone as induction therapy before autologous stem cell transplantation was superior to vincristine-adriamycin-dexamethasone. We conducted a post-hoc analysis to assess the prognostic impact of initial characteristics as well as response to therapy in patients enrolled in this study. Multivariate analysis showed that ISS stages 2 and 3 and achievement of response less than very good partial response (VGPR) both after induction therapy and after autologous stem cell transplantation were adverse prognostic factors for progression-free survival, the most important one being achievement of response less than VGPR after induction. Progression-free survival was significantly improved with bortezomib-dexamethasone induction therapy in patients with poor-risk cytogenetics and ISS stages 2 and 3 compared with vincristine-adriamycin-dexamethasone. In these 2 groups of patients, achievement of at least VGPR after induction was of major importance. This study is registered with EudraCT (https://eudract.ema.europa.eu; EUDRACT 2005-000537-38) and http://clinicaltrials.gov (NCT00200681).
Pubmed
Web of science
Open Access
Oui
Création de la notice
18/02/2011 15:07
Dernière modification de la notice
20/08/2019 14:49
Données d'usage